AFL.NYSEAflac INC
10-K: Aflac Reports Strong 2024 Earnings, Cites Growth in Key Segments
Sentiment:
Annual Results
Aflac Incorporated announces a 1.2% increase in total revenues and a significant rise in net earnings for the fiscal year ended December 31, 2024, driven by strategic growth initiatives and effective capital deployment.
Capital raiseIn September 2024, the Parent Company filed a shelf registration statement with the SEC that allows the Company to issue an indefinite amount of debt securities, in one or more series, from time to time until September 2027.
Summary
- Aflac Incorporated reported a 1.2% increase in total revenues, reaching $18.9 billion for the full year 2024.
- Net earnings for 2024 were $5.4 billion, or $9.63 per diluted share, compared to $4.7 billion, or $7.78 per diluted share, in 2023.
- Adjusted earnings for 2024 reached $4.1 billion, or $7.21 per diluted share, up from $3.7 billion, or $6.23 per diluted share, in 2023.
- The average yen/dollar exchange rate in 2024 was 150.97, a 6.9% weakening compared to 140.57 in 2023, negatively impacting adjusted earnings per diluted share by $0.18.
- Aflac repurchased 30.4 million of its common shares for $2.8 billion in 2024, with 47.3 million shares remaining authorized for repurchase at year-end.
- Shareholders' equity increased to $26.1 billion, or $47.45 per share, at the end of 2024, including a $2.0 billion cumulative increase from changes in discount rate assumptions on insurance contracts.
- The annualized return on average shareholders' equity in 2024 was 22.6%.
- The company's long-term strategy focuses on growth, strong profit margins, and tactical capital deployment through product development and distribution expansion.
- For 2025, Aflac anticipates stable benefit ratios in Aflac Japan and growth in life and disability to increase benefit ratios in Aflac U.S.
Sentiment
Score: 7
Explanation: The document presents a generally positive outlook with strong earnings and strategic growth plans, but also acknowledges some challenges and risks.
Positives
- The company's strategy to drive long-term shareholder value is to pursue growth and strong profit margins and to exercise tactical capital deployment.
- The company's objectives in 2025 include maintaining strong pretax margins with increased sales production through product refreshments and growth initiatives in both its Aflac Japan and Aflac U.S. segments.
- The company intends to maintain strong capital ratios in Aflac Japan and Aflac U.S. in support of its commitment to shareholder dividends while remaining tactical in its deployment of capital in the form of share repurchases and opportunistic investments.
Negatives
- The weaker yen/dollar exchange rate negatively impacted adjusted earnings per diluted share by $0.18.
- Shareholders equity at December 31, 2024 included an unrealized foreign currency translation loss of $5.0 billion.
- The company expects that benefit and expense ratios will continue to experience some level of revenue pressure due to the impact of paid up policies and internal reinsurance transactions.
Risks
- Difficult conditions in global capital markets and the economy could have a material adverse effect on the Company's investments, capital position, revenue, profitability, and liquidity and harm the Company's business.
- The Company is exposed to significant interest rate risk, which may adversely affect its results of operations, financial condition and liquidity.
- The Company's concentration of business in Japan poses risks to its operations and financial condition.
- Lack of availability of acceptable yen-denominated investments could adversely affect the Company's results of operations, financial position or liquidity.
- The Company is exposed to foreign currency fluctuations in the yen/dollar exchange rate.
- If future policy benefits, claims or expenses exceed those anticipated in establishing premiums and reserves, the Company's financial results would be adversely affected.
Future Outlook
The Company's strategy to drive long-term shareholder value is to pursue growth and strong profit margins and to exercise tactical capital deployment. The Company's objectives in 2025 include maintaining strong pretax margins with increased sales production through product refreshments and growth initiatives in both its Aflac Japan and Aflac U.S. segments.
Management Comments
- The Company's strategy to drive long-term shareholder value is to pursue growth and strong profit margins and to exercise tactical capital deployment.
- The Company's approach to pursue growth is through product development and distribution expansion and to achieve efficiencies by modernizing its technology and streamlining its operations.
- The Company believes that its strategy of positioning itself for future growth and efficiency while defending and leveraging its market-leading position, powerful brand recognition and varied distribution in Japan and the U.S. will provide support toward these objectives.
Industry Context
The Company is impacted by financial markets, economic conditions, regulatory oversight and a variety of trends that affect the industries where it competes. With Japans aging population and the rise in healthcare costs, supplemental health care insurance products remain attractive. Additionally, as Japan enters an era of 100-year lifespans, customers' needs for asset formation and retirement coverage, including nursing care, are increasing.
Comparison to Industry Standards
- The S&P 500 Life and Health Insurance Index includes: Aflac Incorporated, Globe Life Inc., MetLife Inc., Principal Financial Group Inc. and Prudential Financial Inc.
- The Company competes with other insurers and financial institutions primarily on the basis of its products, compensation, support services and financial rating.
- The Company also faces potential competition from existing or new companies in the U.S. and Japan that have not historically been active in the supplemental health insurance industry, but some of which have greater financial, marketing and management resources than the Company.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Executive Vice President, General Counsel of Corporation | Executive Vice President, General Counsel of Corporation | Senior Executive Vice President, General Counsel of Corporation | January 1, 2025 | Corporation has created a new, more senior title for certain officers and has determined that Employee should be awarded such title |
| Executive Vice President, Chief Financial Officer and Treasurer of Corporation | Executive Vice President, Chief Financial Officer and Treasurer of Corporation | Senior Executive Vice President, Chief Financial Officer of Corporation | January 1, 2025 | Corporation has created a new, more senior title for certain officers and has determined that Employee should be awarded such title |
Legal Proceedings
- The Company is a defendant in various lawsuits and receives various regulatory inquiries considered to be in the normal course of business.
Stakeholder Impact
- The Company intends to maintain strong capital ratios in Aflac Japan and Aflac U.S. in support of its commitment to shareholder dividends while remaining tactical in its deployment of capital in the form of share repurchases and opportunistic investments.
Next Steps
- The Company intends to maintain strong capital ratios in Aflac Japan and Aflac U.S. in support of its commitment to shareholder dividends while remaining tactical in its deployment of capital in the form of share repurchases and opportunistic investments.
Key Dates
| Date | Description |
|---|---|
| 1973 | Aflac Incorporated was incorporated in the state of Georgia. |
| 1974 | Aflac Japan pioneered the cancer insurance market in Japan. |
| 1995 | The Private Securities Litigation Reform Act of 1995 provides a safe harbor to encourage companies to provide prospective information. |
| 1999 | Aflac had been running commercials for nearly a decade, but its brand awareness was hovering at about 10%. |
| January 1, 2000 | The Aflac Duck's first commercial in the U.S., Park Bench, aired. |
| 2001 | Aflac Japan's alliance with Dai-ichi Life was launched. |
| 2001 | The deregulation of the Japan market in 2001 more than doubled the number of insurance companies offering stand-alone cancer and medical insurance. |
| 2003 | The Aflac Duck made its international debut in Japan. |
| 2008 | Aflac Japan's alliance with Japan Post Group was launched. |
| 2009 | Aflac Heartful Services Co., Ltd. was established. |
| 2010 | The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), federal health care reform legislation, gave the U.S. federal government direct regulatory authority over the business of health insurance. |
| 2010 | Title VII of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (Dodd-Frank) and regulations issued thereunder, in particular rules to require central clearing for certain types of derivatives, may have an impact on the Company's derivative activity, including activity on behalf of Aflac Japan. |
| 2013 | Aflac Japan and Daido Life Insurance entered into an agreement for Daido to sell Aflac Japan's cancer insurance products specifically to the Hojinkai market. |
| 2013 | The alliance between Aflac Japan and Japan Post Group strengthened. |
| 2014 | Charles D. Lake II became President, Aflac International. |
| 2018 | Aflac Japan was converted to a Japan subsidiary from a branch of Aflac. |
| 2018 | Masatoshi Koide became President and Representative Director, Aflac Japan. |
| 2018 | Charles D. Lake II became Chairman and Representative Director, Aflac Japan. |
| 2018 | Aflac Japan launched Prepare Smart Whole-Life Insurance. |
| December 19, 2018 | The Parent Company and Aflac Japan entered into a Basic Agreement with Japan Post Holdings Co., Ltd. |
| February 28, 2019 | The Shareholders Agreement was entered into by the Parent Company, Japan Post Holdings Co., Ltd., J&A Alliance Holdings Corporation, and General Incorporated Association J&A Alliance. |
| 2019 | Aflac acquired Aflac Benefits Solutions, Inc. |
| January 2021 | Aflac Japan implemented a human capital management system, beginning with managers and more senior leadership positions. |
| January 2022 | Aflac Japan implemented a human capital management system with all other employees. |
| August 2022 | Aflac Japan launched a new cancer insurance product, WINGS. |
| November 2022 | The board of directors announced a 100,000,000 share repurchase authorization. |
| January 2023 | Aflac Japan launched Aflac Yorisou Cancer Consultation Support. |
| May 1, 2023 | The Parent Company filed a registration statement on Form S-3 that registered the sale of its common stock from time to time by J&A Alliance Holdings Corporation in its capacity as trustee of the Trust. |
| September 2023 | Aflac Japan launched a new medical insurance product designed to appeal to younger policyholders with basic needs and existing policyholders who desire additional or updated coverage. |
| 2023 | The NYSDFS commenced a routine market conduct examination on Aflac New York covering the five-year period ended on December 31, 2022 that is currently ongoing. |
| 2023 | The Company amended the U.S. defined benefit plan to freeze future benefits under the plan for all participants effective January 1, 2024. |
| March 2024 | The Bank of Japan ended its policy of negative interest rates. |
| March 2024 | The Parent Company issued five series of senior notes totaling 75.0 billion through a private placement. |
| March 2024 | The Parent Company issued three series of senior notes totaling 48.6 billion through a public debt offering under its U.S. shelf registration statement. |
| April 2024 | ALIJ redeemed 30.0 billion of its .963% subordinated bonds due April 2049. |
| May 10, 2024 | The Parent Company reported that the shares owned by the J&A Alliance Trust represented, in aggregate, 20% of the voting power of the Parent Company's common stock. |
| June 2024 | Aflac Japan launched Tsumitasu, an insurance product designed primarily for post-retirement preparation, with asset formation features and coverage for nursing care and other benefits. |
| September 2024 | The Parent Company filed a shelf registration statement with the SEC that allows the Company to issue an indefinite amount of debt securities, in one or more series, from time to time until September 2027. |
| December 2024 | The board of directors announced a 16.0% increase in the quarterly cash dividend, effective with the first quarter of 2025. |
| December 31, 2024 | Aflac Japan was represented by approximately 6,600 sales agencies, with approximately 114,000 licensed sales associates employed by those agencies. |
| January 2025 | Aflac Japan was certified, for the seventh consecutive year, as one of the top 500 Leading Companies in Health and Productivity Management under the Certified Health & Productivity Management Outstanding Organizations Recognition Program with Japan's Ministry of Economy, Trade and Industry. |
| January 2025 | The Company purchased a nonparticipating single premium group annuity contract from an external insurer to settle its obligations under the U.S. defined pension plan. |
| January 16, 2025 | Japan Post Holdings filed a Form 13F with the SEC, reporting ownership of 52.3 million Aflac Incorporated common shares as of December 31, 2024. |
| February 18, 2025 | There were 78,663 holders of record of the Company's common stock. |
| March 3, 2025 | The first quarter 2025 cash dividend of $.58 per share is payable to shareholders of record at the close of business on February 19, 2025. |
| April 1, 2025 | The external insurer will begin making annuity payments to plan participants. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.